Cullinan Oncology, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cullinan Oncology, LLC - overview
Established
2017
Location
Cambridge, MA, US
Primary Industry
Pharmaceuticals
About
Based in Massachusetts, US, and founded in 2017 by co-founders Patrick Baeuerle, Ph. D. , and Karl Wittrup, Ph. D.
, Cullinan Oncology, LLC operates as a developer of therapeutics for the treatment of cancer. Park Vale Capital, Baupost Group, Eventide Asset Management, and Logos Capital fully exited their stake in Cullinan Oncology, LLC, for an undisclosed amount. As of 2024, the company is led by its CEO, Nadim Ahmed. The firm trades on NASDAQ under the Ricker symbol CGEM.
The company provides a wide range of therapeutic products, such as monoclonal antibodies, small molecules, and bispecific antibodies for oncology and autoimmune indications.
Current Investors
MPM BioImpact, F2 Ventures, Park Vale Capital
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Cardiology, Pharmaceutical Research & Development
Website
www.cullinanoncology.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Cullinan Oncology, LLC - timeline of key events
Cullinan Oncology, LLC - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | 18,943,000 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (14,543,000) | (22,200,000) | (60,040,000) | (64,803,000) | 146,035,000 | - | - | - |
| Operating Income (USD) | (14,586,000) | (22,270,000) | (60,335,000) | (67,954,000) | 144,648,000 | - | - | - |
| Operating Margin | - | - | - | (358.7%) | - | - | - | - |
| % EBITDA Margin | - | - | - | (342.1%) | - | - | - | - |
| NET Income (USD) | (14,189,000) | (21,654,000) | (59,458,000) | (67,485,000) | 109,195,000 | - | - | - |
| % Net Margin | - | - | - | (356.3%) | - | - | - | - |
Cullinan Oncology, LLC - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Cullinan Oncology, LLC | - |
Displaying 1 - 1 of 1
Cullinan Oncology, LLC - employee data
Cullinan Oncology, LLC - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| President & CEO & Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.